This editorial refers to 'Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry', by J. Papp et al., Eur Heart J Cardiovasc Pharmacother. 2017;3:147-150.
Since cardioversion in atrial fibrillation (AF) confers an increased risk for thrombo-embolic events, current guidelines recommend at least 3 weeks of oral anticoagulation (OAC) prior to cardioversion, followed by a continued anticoagulation for a minimum of 4 weeks after cardioversion. In this regard, vitamin K antagonists (VKAs; e.g warfarin) have traditionally been used for OAC since 1954 and gained in reputation after the-at that time acting-President of the USA, Dwight D. Eisenhower, was being treated with warfarin as one of the first recipients. However, the use of VKAs is associated with various limitations and both inter-and intra-patient variabilities, posing a major need for continuous monitoring of the therapeutic anticoagulation effect using international normalized ratio (INR) values. Time to reach INR target ranges can be prolonged in some individuals, hence delaying the total cardioversion procedure or lowering the efficacy of anticoagulation. Of note, support for the use of warfarin during cardioversion does not derive from randomized trials but from observational cohort studies.
In the early 2010s, several non-vitamin K antagonist oral anticoagulants (NOACs) were introduced to the market as an alternative in the reduction of thrombo-embolic events. As a major benefit, those drugs overcame the necessity for laboratory monitoring of VKAs with an at least non-inferior efficacy and safety, leading to a quick expansion of their scope of application.
In 2014 the results of the X-VeRT trail-the first randomized controlled trial on NOACs during cardioversion-showed comparable risks for thrombo-embolic events and bleeding, comparing rivaroxaban with standard warfarin therapy during elective cardioversion in AF.
1 Similar results applied for the second randomized controlled trial (ENSURE-AF) comparing edoxaban with warfarin, demonstrating non-inferiority. 2 Those large randomized controlled trials as well the post-hoc analysis of RE-LY and ARISTOTLE indicated that NOACs are at least non-inferior to VKA in the prevention of major strokes in individuals with AF, and therefore safe and feasible alternatives for anticoagulation during cardioversion.
3,4
The impact of evidence While the first trial on NOACs in AF was already published 8 years ago, there have been no data in the literature so far on how data from randomized controlled trials might have influenced OAC strategies in patients undergoing cardioversion. In this regard, Papp and co-workers added important knowledge in this field, demonstrating in the present issue temporal trends in the use of VKAs and NOACs for cardioversion in AF from a European multicentre perspective. 5 While they found that 68.5% of all individuals received VKAs, NOACs still appear to be used only in a limited number of patients around cardioversion. Of note, the de novo prescription of VKAs and NOACs was comparable. However, during the observation period from September 2014 until October 2015, a significant decrease in the use of VKAs and a concomitant increase of the use of rivaroxaban and apixaban was observed. Interestingly, the use of dabigatran remained stable.
In two recent publications from nationwide registries, the use of NOACs was more than twice as high as that in the study of Papp et al., amounting to 65% (Denmark) and 74% (Norway), respectively. 6, 7 However, in accordance with the present results, they observed a similar decrease in the use of VKAs and an increasing fraction of NOACs. Moreover, they found an analogue trend of an increasing use of both apixaban and rivaroxaban.
The observed increase of rivaroxaban among all mentioned studies might mirror the presentation of the results of the X-VeRT trial. 4 This first randomized controlled trial on NOACs during cardioversion demonstrated safety and efficacy compared with warfarin. The data of Staerk et al. impressively illustrated a stable use of rivaroxaban prior to X-VeRT and a strong increase after the study was published in 2014. 6 The subgroup analysis of the ARISTOTLE trial indicated that treatment with apixaban during cardioversion is associated with a low risk found that dabigatran was the most prescribed NOAC for OAC within the first months of their observations, followed by a consistent decline in their use most probably due to a more competitive market with the availability of different NOACs. 5, 6 The financial burden of oral anticoagulation
The choice of OAC might also be a question of the financial impact of the respective drug. Compared with NOACs, the use of VKAs in AF is associated with significantly lower direct drug costs. From a socio-economic perspective, it seems intuitive, therefore, that NOACs might be less prescribed among European countries showing a lower gross domestic product (GDP). While the present study of Papp and co-workers investigated data from France, Italy, Hungary, Lithuania, and Spain, national surveys are also available for both Denmark and Norway. 6, 7 Comparing the annually reported health spending per GDP for all those countries-reported by the OECD (Organization for Economic Co-Operation and Development)-with the fraction of NOAC use within OAC therapy during cardioversion, there is an increased use of NOACs in countries with higher health spending per GDP. (Figure 1 ). These data suggest that NOACs are less likely to be prescribed in countries with lower health spending-indicating a strong potential influence of the countries' individual healthcare policy on the choice of the respective OAC agent.
Conclusion and future perspectives
From a European perspective, the use of VKAs for anticoagulation in patients with AF during cardioversion is continuously decreasing. NOACs proved to be a safe and feasible alternative to VKAs, gaining in popularity, but still showing differences of their prescription among European countries, ranging from 11% in Spain to 76% in Denmark.
Since the increasing overall prescription of NOACs seems to be affected by evidence from randomized controlled trials, the about equally frequent de novo prescription of NOACs and VKAs in patients undergoing cardioversion might also be influenced by individual considerations on potential advantages and disadvantages of the respective agents. A perceived advantage of VKAs in the situation of cardioversion is the control of adherence by laboratory monitoring. A perceived advantage of NOACs is the rapid and predictable therapeutic effect, shortening the time until cardioversion. In contrast, only 76% of all patients receiving VKAs presented with a therapeutic INR value >2 at the time of cardioversion, leaving about a quarter of patients without sufficient protection against thrombo-embolic events. 
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